六福(00590.HK)第二財季整體同店銷售按年升1.05倍
六福(00590.HK)公布截至2022年3月31日止財政年度第二季,即今年7月1日至9月30日期間銷售表現。由於低基數效應及新冠疫情有效控制,整體同店銷售按年上升105%,黃金及定價首飾同店銷售分別升116%及89%。
期內,香港及澳門市場同店銷售增長按年升109%。在低基數效應的情況下,澳門市場第二季同店銷售增長達326%。香港市場的同店銷售增長亦升至63%。另外,香港及澳門市場於季內的零售銷售金額按年計約有110%升幅。
內地自營店於第二季同店銷售增長為62%,其黃金產品及定價首飾產品的同店銷售增長分別為115%及跌5%。內地電子商務業務第二季的銷售金額按年計則錄得65%的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.